Lexaria Bioscience Corp. (NASDAQ: LEXX) was recently part of coverage by Zacks Small-Cap Research analysts based on its market potential. Zacks, which focuses its coverage on small and micro-cap companies it regards as under-followed or under-valued by the broader market in an effort to benefit investors as well as worthy innovators, valued the company at $15 per share. The valuation was based on the company’s portfolio supporting Lexaria’s patented DehydraTECH(TM) consumption and the multiple potential uses of the technology. The technology is also relatively low-cost, with the capacity to produce up to 400,000 consumer packaged goods through existing manufacturer relationships. A recent article reads, “Zacks notes the potential market reach of Lexaria’s technology if regulatory approved for use in pharmaceuticals, given that hypertension affects about 150 million people nationwide and over a billion worldwide, many of whom find existing medicines less than optimal. The ongoing COVID pandemic has also heightened attention on the need for antivirals to treat ever-present virus infections. And there are about a billion smokers worldwide who could potentially benefit from alternative methods of delivering nicotine to avoid the lung-deleterious effects of inhaling burned or vaporized substances.”
To view the full article, visit https://cnw.fm/w03ju
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1-2 hours to minutes and mask unwanted tastes; it is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.HempWire.com
Do you have questions or are you interested in working with HW? Ask our Editor
HempWire is part of the InvestorBrandNetwork.